OGN News and Press, Organon & Co. From 08/12/21

The following slide deck was published by Organon & Co. in conjunction with their 2021 Q2 earnings call. For further details see: Organon & Co. 2021 Q2 - Results - Earnings Call Presentation

Second quarter 2021 revenue of $1,595 million Net income from continuing operations of $431 million, or $1.70 per diluted share; Adjusted net income from continuing operations of $437 million, or $1.72 per diluted share Adjusted EBITDA of $627 million Board of Directors de...

AZEK,AZUL,BIDU,BR,CELH,CSIQ,CYBR,EYE,GDRX,GRWG,IQ,KELYA,MDP,MIDD,MSGS,OGN,PLTR,SDGR,TAL,UTZ,ZNTL For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

Kahn Brothers’ 13F portfolio value increased from $646M to $698M this quarter. BP plc and Pfizer were increased, while decreasing Nam Tai Property and BlackBerry during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~...

TolikoffPhotography/iStock via Getty Images Organon (OGN) and ObsEva (OBSV) have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022), being evaluated as a potential treatment for preterm labor by reducing in...

Organon (NYSE: OGN) will release its second quarter 2021 financial results on August 12, 2021, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET. Interested parties may access the live call via webcast on the Organon website at https://www.organo...

Organon was formed as a result of Big Pharma Merck's decision to spin out its Established Brands, Women's Health and Biosimilars divisions into a new entity. Shares began trading in May, and traded at $37 in early June, before sliding in response to Q121 earnings. Current price is $29...

Organon is the spin-off of Merck's women’s health, legacy products, and biosimilars businesses. Out of older products that do not have much growth in them, there are some bright spots, like birth control implants. Thus, the forecast for 2021 is for revenue to regress furthe...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Strong markets and broader leadership were tailwinds for ...

PPL (NYSE: PPL) , Organon (NYSE: OGN) , and Lordstown Motors (NASDAQ: RIDE) may seem underpriced according to their historical averages, but as plenty of investors know, better past performance is not an indicator of better future results. All three of these stoc...